Do you consider MET amplification in your first-line treatment decisions for patients with metastatic NSCLC?

Answer from: Medical Oncologist at Academic Institution

Not at present and nothing is FDA approved or NCCN guidelines. Second line or later yes, especially on a trial

Comments

Medical Oncologist at Cancer Care Specialists/Renown Oncology/UNR
Agree that currently no FDA approved agents upfron...